ICML 2023 | CHECKMATE 205: factors associated with PFS in patients with R/R HL treated with nivolumab
Sally Barrington, MBBS, MSc, FRCP, FRCR, MD, King’s College London, London, UK, discusses an analysis of the PET-CT data from the CHECKMATE 205 study (NCT02181738), a Phase II trial investigating nivolumab for patients with relapsed/refractory Hodgkin lymphoma (R/R HL). Prof. Barrington shares two key observations from this study: baseline standardized uptake value (SUV) was prognostic for progression-free survival (PFS), and uptake rates in bone marrow and spleen were associated with inferior PFS. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
